Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. reports on events occurring on January 17, 2019. The filing addresses the departure of the Chief Financial Officer and the appointment of an interim successor.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation and severance:
- Severance Pay: $202,000 aggregate amount for the departing CFO.
- Performance Incentive: $173,417 annual performance-based cash incentive for fiscal year 2018.
- Retention Payments: $13,500 lump sum payments scheduled for June 30, 2019, and January 31, 2020, for the interim CFO.
Material Changes
The primary material change is the resignation of Michael Falvey as Executive Vice President, Chief Financial Officer, and Treasurer, effective January 18, 2019. The Company is currently conducting an executive search for a permanent successor.
Outlook, Management Commentary, and Risks
Interim Leadership: Cameron Peters, Vice President, Finance and Assistant Treasurer, has been appointed as the interim principal financial and accounting officer effective January 18, 2019. Mr. Peters has over 25 years of finance experience and has been with the Company since January 2018.
Transition Arrangements: Mr. Falvey will provide advisory services under a consulting agreement until July 18, 2019. His unvested equity awards will continue to vest until April 18, 2019.
Risks: The filing notes the Company is in the process of identifying a permanent CFO, which represents a temporary leadership gap in the finance function.
Investor Verification Checklist
- Verify the timeline for the executive search to identify a permanent CFO.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for additional terms regarding Mr. Falvey's departure.
- Confirm the terms of the Retention Agreement (Exhibit 10.3) for Mr. Peters.
- Monitor future filings for the announcement of the permanent CFO appointment.